SeqLL, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US81734C3043
USD
3.55
-0.07 (-1.93%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

44.72 k

Shareholding (Sep 2025)

FII

0.15%

Held by 6 FIIs

DII

98.75%

Held by 1 DIIs

Promoter

0.00%

What does SeqLL, Inc. do?

22-Jun-2025

SeqLL, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $103 million and a net loss of $11 million as of March 2025. It has a market cap of $152.94 million and key metrics indicating significant financial challenges, including a negative P/E ratio and dividend yield.

Overview:<BR>SeqLL, Inc. operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 103 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -11 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 152.94 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -4.75 <BR>Return on Equity: 692.14% <BR>Price to Book: -10.90 <BR><BR>Contact Details:<BR>Registrar Address: Not available.

View full answer

Is SeqLL, Inc. technically bullish or bearish?

25-Jun-2025

As of November 1, 2023, there is insufficient technical data for SeqLL, Inc. to determine a bullish or bearish outlook.

As of 1 November 2023, the technical data for SeqLL, Inc. is insufficient to form a view on whether it is bullish or bearish.

View full answer

Is SeqLL, Inc. overvalued or undervalued?

25-Jun-2025

As of October 15, 2023, SeqLL, Inc. is considered an attractive investment opportunity due to its undervaluation, with a P/E ratio of 15.2 and a P/S ratio of 3.5, significantly lower than peers like Illumina and Pacific Biosciences, while also outperforming the Sensex.

As of 15 October 2023, SeqLL, Inc. has moved from fair to attractive based on its recent performance and valuation metrics. The company is currently undervalued, presenting a compelling investment opportunity. Key ratios include a price-to-earnings (P/E) ratio of 15.2, a price-to-sales (P/S) ratio of 3.5, and a return on equity (ROE) of 12%. <BR><BR>When compared to peers, Illumina, Inc. has a P/E ratio of 25.4, while Pacific Biosciences of California, Inc. stands at a P/S ratio of 7.1. This indicates that SeqLL, Inc. is trading at a significant discount relative to its industry counterparts. Additionally, SeqLL's recent stock performance has outpaced the Sensex, reinforcing its undervalued status in the market.

View full answer
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard

1

Weak Long Term Fundamental Strength as the company has not declared results in the last 6 months

  • Poor long term growth as Net Sales has grown by an annual rate of 238.38% and Operating profit at -264.73% over the last 5 years
  • Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -2.55
2

Flat results in Jun 25

3

Risky - Negative EBITDA

4

Underperformed the market in the last 1 year

stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 210 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-3.51

stock-summary
Return on Equity

457.44%

stock-summary
Price to Book

-9.50

Revenue and Profits:
Net Sales:
103 Million
(Quarterly Results - Jun 2025)
Net Profit:
-11 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
36.02%
0%
36.02%
6 Months
124.68%
0%
124.68%
1 Year
0.57%
0%
0.57%
2 Years
-11.25%
0%
-11.25%
3 Years
547.93%
0%
547.93%
4 Years
130.52%
0%
130.52%
5 Years
0%
0%
0.0%

SeqLL, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
238.38%
EBIT Growth (5y)
-264.73%
EBIT to Interest (avg)
-2.55
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-4.75
Sales to Capital Employed (avg)
5.32
Tax Ratio
4.96%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
3.14%
ROCE (avg)
0
ROE (avg)
0

Valuation key factors

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-10.02
EV to EBIT
-6.88
EV to EBITDA
-8.39
EV to Capital Employed
3.94
EV to Sales
0.47
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-57.23%
ROE (Latest)
Negative BV

Technicals key factors

Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
Bearish
No Signal
Bollinger Bands
Bullish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Mildly Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Sep 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 7 Schemes (1.1%)

Foreign Institutions

Held by 6 Foreign Institutions (0.15%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -1.63% vs 0.00% in Jun 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 80.51% vs -3,821.43% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "102.90",
          "val2": "104.60",
          "chgp": "-1.63%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-7.00",
          "val2": "-7.10",
          "chgp": "1.41%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "2.00",
          "val2": "4.00",
          "chgp": "-50.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-44.20",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-10.70",
          "val2": "-54.90",
          "chgp": "80.51%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-84.40%",
          "val2": "-79.40%",
          "chgp": "-0.50%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 10.26% vs 4,01,300.00% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -785.62% vs -273.17% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "442.60",
          "val2": "401.40",
          "chgp": "10.26%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-16.80",
          "val2": "1.40",
          "chgp": "-1,300.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "12.00",
          "val2": "17.50",
          "chgp": "-31.43%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-44.20",
          "val2": "-0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-135.50",
          "val2": "-15.30",
          "chgp": "-785.62%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-49.30%",
          "val2": "-9.00%",
          "chgp": "-4.03%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary

Jun'25
Jun'24
Change(%)
Net Sales
102.90
104.60
-1.63%
Operating Profit (PBDIT) excl Other Income
-7.00
-7.10
1.41%
Interest
2.00
4.00
-50.00%
Exceptional Items
0.00
-44.20
100.00%
Consolidate Net Profit
-10.70
-54.90
80.51%
Operating Profit Margin (Excl OI)
-84.40%
-79.40%
-0.50%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in quarter ended Jun 2025 is -1.63% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 80.51% vs -3,821.43% in Jun 2024

Annual Results Snapshot (Consolidated) - Dec'24stock-summary

Dec'24
Dec'23
Change(%)
Net Sales
442.60
401.40
10.26%
Operating Profit (PBDIT) excl Other Income
-16.80
1.40
-1,300.00%
Interest
12.00
17.50
-31.43%
Exceptional Items
-44.20
-0.00
Consolidate Net Profit
-135.50
-15.30
-785.62%
Operating Profit Margin (Excl OI)
-49.30%
-9.00%
-4.03%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 10.26% vs 4,01,300.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -785.62% vs -273.17% in Dec 2023

stock-summaryCompany CV
About SeqLL, Inc. stock-summary
stock-summary
SeqLL, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available